https://www.selleckchem.com/pr....oducts/bgj398-nvp-bg
8% in non-treated zone. Regarding morbidities, urinary incontinence appeared in 7.5% and erectile dysfunction rate was 13.2%. Our study reveals the first experience of HIFU by Focal One® device in an Afro-Caribbean population. It seems to be a safe and reproducible treatment with acceptable oncological results and low genitourinary morbidity. Long term follow-up and a higher number of patients are necessary to validate these results. Our study reveals the first experience of HIFU by Focal One® device in an Afro-Caribbean popul
Like
Comment
Share
